Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma

Summary

GBM is the most common intracranial tumor in adults, accounting for about 40% of all primary intracranial tumors.Although surgery, radiotherapy and chemotherapy have been used, the prognosis of glioma patients is still very poor. The study aim to Evaluate the Safety and efficiency of Using the neoadjuvant therapy with Carilizumab and Apatinib in patients with Recurrent High-Grade Glioma.

Timeline

Start

2020-10

Primary completion

2023-10

Completion

2024-05

Drugs

Indications